Trial Profile
An Open-Label Extension Study of 12 mg Proellex (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Jun 2018
Price :
$35
*
At a glance
- Drugs Telapristone (Primary)
- Indications Uterine leiomyoma
- Focus Therapeutic Use
- Sponsors Repros Therapeutics
- 25 Jul 2017 Status changed from active, no longer recruiting to discontinued due to Business decision.
- 05 Jul 2016 New trial record